> It seems a lot of people don't really want to discuss this, but I think the facts are relatively clear: The mRNA vaccines have an effectiveness above 90% and

> It seems a lot of people don't really want to discuss this, but I think the facts are relatively clear: The mRNA vaccines have an effectiveness above 90% and none of the others comes close to that. Biontech and Moderna are so close to each other that there's probably no argument for either of those. There are error bars on those point estimates, and they're wide, because the trials didn't have a huge number of hospitalizations or deaths. You also can't compare them across trials, because they were tested on different populations, at different times, under different conditions (i.e. dominant variants, but also temperature, disease prevlance, etc.) Based on everything I've seen so far, the approved vaccines are all essentially statistically indistinguishable, with the caveat that the J&J vaccine is one dose, the mRNA vaccines are two, and the AZ trial was kind of a mess. But the choice of dosing strategy was always somewhat arbitrary, based on the inherent sloppiness of a combined phase 1/2 trial. Had Pfizer and Moderna decided to go with a one-shot regimen, the trial would have reported a very similar effectiveness profile to J&J. I strongly suspect we'll see better data on all three that will put them within a margin of error of each other, and suggest better dosing strategies.